BrainsWay (NASDAQ:BWAY – Get Free Report) and Tenon Medical (NASDAQ:TNON – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, risk, earnings and profitability.
Institutional & Insider Ownership
30.1% of BrainsWay shares are owned by institutional investors. Comparatively, 22.7% of Tenon Medical shares are owned by institutional investors. 19.0% of BrainsWay shares are owned by company insiders. Comparatively, 4.7% of Tenon Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Valuation & Earnings
This table compares BrainsWay and Tenon Medical”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BrainsWay | $31.78 million | 5.40 | -$4.20 million | $0.10 | 102.81 |
| Tenon Medical | $2.93 million | 2.27 | -$15.58 million | ($27.23) | -0.08 |
Profitability
This table compares BrainsWay and Tenon Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BrainsWay | 3.88% | 3.52% | 2.26% |
| Tenon Medical | -413.88% | -1,785.88% | -164.26% |
Risk & Volatility
BrainsWay has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500. Comparatively, Tenon Medical has a beta of 1.92, meaning that its share price is 92% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent ratings for BrainsWay and Tenon Medical, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BrainsWay | 0 | 0 | 3 | 0 | 3.00 |
| Tenon Medical | 0 | 0 | 2 | 0 | 3.00 |
BrainsWay presently has a consensus target price of $13.17, suggesting a potential upside of 28.08%. Tenon Medical has a consensus target price of $5.50, suggesting a potential upside of 159.43%. Given Tenon Medical’s higher probable upside, analysts plainly believe Tenon Medical is more favorable than BrainsWay.
Summary
BrainsWay beats Tenon Medical on 11 of the 13 factors compared between the two stocks.
About BrainsWay
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. BrainsWay Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
About Tenon Medical
Tenon Medical, Inc., a medical device company, engages in the development of surgical implant systems to treat severe lower back pain in the United States and Puerto Rico. The company offers CATAMARAN SI-Joint Fusion System to fuse sacroiliac joints (SI-Joints) to treat SI-Joint dysfunction that often causes severe lower back pain; and features fixation device that passes through the axial and sagittal planes of the ilium and sacrum, as well as transfixes the SI joints. Tenon Medical, Inc. was incorporated in 2012 and is headquartered in Los Gatos, California.
Receive News & Ratings for BrainsWay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BrainsWay and related companies with MarketBeat.com's FREE daily email newsletter.
